(Reuters) – Major U.S. laboratory Quest Diagnostics (NYSE:) Inc posted a 241% rise in second-quarter profit on Thursday, as vaccine rollouts and a drop in COVID-19 cases spurred a recovery in its core non-coronavirus testing businesses.
Net income attributable to the company rose to $631 million, or $4.96 per share, in the second quarter ended June 30, from $185 million, or $1.36 per share, a year earlier.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Need Your Help Today. Your $1 can change life.